Managing hemophilia with inhibitors can bring challenges
Living with hemophilia B with inhibitors, you may face serious challenges and potential risks with limited treatment options.
Bleeds can lead to joint damage, so having preventative treatment is essential
In a real-world study of people with hemophilia, including hemophilia B with inhibitors:
Median Annual Bleed Rate
Bleeds per year
when using bypassing agents on demand
(16 people)a
Bleeds per year
when using bypassing agents as prophylaxis
(15 people)a
aThis study looked at past records of patients with hemophilia, including 31 male adults and adolescents aged 12 years and older who have hemophilia B with inhibitors, of any severity. It aimed to learn more about their everyday needs. In the study, 16 of them used bypassing agents only when a bleed happened (on demand), and on average, they used this treatment for about 9 years (111 months). The other 15 people used these treatments as a preventive prophylaxis, doing so for around 7 years (85 months) on average. The study also looked at how often bleeds happened each year (median bleeds per year).
Until now, your only option for bleed protection has left you vulnerable to
Severe allergic reactions
(anaphylaxis)
Numerous IV administration
steps including mixing
Multiple IV infusions per week for prophylaxis
You deserve daily bleed protection with a treatment made with your challenges in mind
For people living with hemophilia A with inhibitors, you deserve more options to protect against bleeds
Unpredictable bleeds persist
~50% (70 people) of patients on nonfactor therapy that works like Factor 8 (Factor 8 mimetic) experienced at least 1 spontaneous bleed.
In a real-world observational study conducted by the Israeli National Hemophilia Center that observed the breakthrough bleeding patterns were analyzed in patients with severe hemophilia A, with or without inhibitors, receiving prophylactic Factor 8 mimetic therapy and completing ≥18 months of follow-up (n=28 patients with hemophilia A with inhibitors). Results include people who have hemophilia A with or without inhibitors (42 patients without inhibitors). Findings have not been confirmed by a clinical or randomized controlled trial.
~55% of patients on bypassing agent prophylaxis experienced at least 1 spontaneous bleed.
In a study conducted in Europe that observed real-world use of aPCC for patients with hemophilia A with inhibitors or hemophilia B with inhibitors, receiving aPCC treatment on demand or prophylactically for more than 4 years in routine clinical practice (n=36 patients with hemophilia A with inhibitors and 1 patient with hemophilia B with inhibitors received aPCC prophylaxis). Findings have not been confirmed by a clinical or randomized control trial.
aPCC=activated prothrombin complex concentrate.
TALK TO YOUR DOCTOR about a solution that helps address your needs and supports you in achieving your goals.
Heavy treatment burden adds to the challenge
Time-consuming administration
Nonfactor therapy can take up to 15 minutes to prepare and inject with vials and syringes.
Pain and discomfort
May include using large, thick needles (23G-27G) for injections.
Complicated administration
Multiple steps and supplies to prepare and administer treatment.
You should expect your treatment to work the way you need it to
